Ginkgo Bioworks Holdings Inc vs Ford Motor Company — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Ford Motor Company trades at $13.84 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 110.2× Ginkgo Bioworks Holdings Inc's market cap, and Ford Motor Company pays a 4.29% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | F | |
|---|---|---|
Market Cap | $505.73M | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $17.44 |
52-Week Low | $5.48 | $11.21 |
Enterprise Value | $607.68M | $187.71B |
Dividend Yield | — | 4.29% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Ford Motor Company (F) trades at $13.865, down 1.07% on the day, with a bearish technical signal. Recent earnings show volatility, with Q2 2026 beating expectations but Q4 2025 missing. The company reported a net loss of $8.18B in 2025 despite $187.27B revenue, though operating cash flow remains strong at $21.28B. News highlights the upcoming Fathom EV truck priced at $28,350, targeting affordability in 2027.
The outlook is mixed; low P/E of 11.84 and analyst consensus price target of $16.18 suggest potential upside, but negative net income margin and high debt pose risks. Investor sentiment is cautious amid EV transition costs and competitive pressures, with 38.3% of analysts rating Buy. Key opportunities include new affordable models and strong cash flow, while execution on profitability remains critical.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →